Skip to content

Efficacy of laryngeal anesthesia with a double-lumen airway route topical anesthesia for intubation stress

Efficacy of laryngeal anesthesia with a double-lumen airway route topical anesthesia for intubation stress

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089006
Enrollment
Unknown
Registered
2024-08-30
Start date
2024-09-02
Completion date
Unknown
Last updated
2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with lung surgery

Interventions

group A:Laryngeal anesthetic tube is given 10ml of normal saline for the airway path of the double lumen tube
group B:Laryngeal anesthetic tube is given to the double-lumen tube airway path 2% lidocaine 10 ml
group C:Laryngeal anesthetic tube is given to the double-lumen tube airway pathway alkalinized lidocaine (2% lidocaine 9ml + 5% sodium bicarbonate solution 1ml) 10ml

Sponsors

Anhui Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Age 18~75 years old; 2) ASA: I~III level; 3) Patients undergoing thoracic surgery who are going to undergo double-lumen bronchial intubation; 4) Agree to participate in the clinical study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) predict difficult airway. 2) allergy to topical anesthesia or other anesthetics. 3) severe arrhythmias, such as HR=50 bpm at rest, conduction block (double bundle branch block, second- or third-degree block), frequent premature ventricular contractions, QTc: =450 ms for males, =470 ms for females. 4) poorly controlled hypertension (sitting systolic blood pressure (SBP) = 160 mmHg and/or sitting diastolic blood pressure (DBP) =100 mmHg) taking antihypertensive drugs). 5) Severe heart and brain organic lesions, severe liver and kidney dysfunction and endocrine diseases. 6) Patients with psychiatric illness, long-term use of psychotropic drugs, or cognitive dysfunction judged to be lacking the ability to give informed consent. 7) Pregnant or lactating patients. 8) Other patients who are considered by the investigators to be unsuitable to participate in this program.

Design outcomes

Primary

MeasureTime frame
Incidence of reactive tachycardia (>120bpm).;Incidence of reactive hypertension (> basal value 130%);

Secondary

MeasureTime frame
Heart rate;Mean arterial pressure;Choking;Hoarseness and sore throat;Incidence of respiratory-related complications (atelectasis, hypoxemia, pulmonary infection).;

Countries

China

Contacts

Public ContactSusu Zhou

Anhui Provincial Hospital

383119260@qq.com+86 134 8571 3512

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026